A Case of Acute Pulmonary Thromboembolism after Taking Tadalafil.
10.4046/trd.2012.73.4.231
- Author:
Jinwoo LEE
1
;
Ji Hyun KWON
;
Chang Hoon LEE
;
Sang Min LEE
;
Jae Joon YIM
;
Chuy Gyu YOO
;
Young Whan KIM
;
Sung Koo HAN
;
Young Sik PARK
Author Information
1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Lung Institute, Seoul National University College of Medicine, Seoul, Korea. mdyspark@gmail.com
- Publication Type:Case Report
- Keywords:
Pulmonary Embolism;
Pulmonary Infarction;
Tadalafil;
Phosphodiesterase 5 Inhibitors;
Factor VIII
- MeSH:
Blood Coagulation Factors;
Carbolines;
Cyclic Nucleotide Phosphodiesterases, Type 5;
Drug Toxicity;
Erectile Dysfunction;
Factor VIII;
Humans;
Male;
Middle Aged;
Phosphodiesterase 5 Inhibitors;
Pulmonary Embolism;
Pulmonary Infarction;
Thrombosis;
Tadalafil
- From:Tuberculosis and Respiratory Diseases
2012;73(4):231-233
- CountryRepublic of Korea
- Language:English
-
Abstract:
Tadalafil is a phosphodiesterase-5 inhibitor (PDE5I), which is widely used to treat erectile dysfunction. Although PDE5Is have excellent safety profiles, and most of the side effects are mild, rare serious adverse events have been reported in association with PDE5Is. Thrombosis is one of those events, and a few previous reports have suggested the association of PDE5Is with thrombosis. We report the case of a 61-year-old male who developed pulmonary embolism combined with pulmonary infarction directly after taking tadalafil. Both the patient and the physician suspected tadalafil as the culprit drug, as the patient was in an otherwise healthy condition. However, after extensive evaluation, we noticed that factor VIII levels were elevated. Prior reports suggesting the association between thrombosis and PDEIs either lack complete information on coagulation factors, or show inconsistencies in their results. Physicians should operate caution prior to accepting the diagnosis of adverse drug reaction.
